

Part VI: Summary of the risk management plan

Summary of risk management plan for Bortezomib beta 3,5 mg Pulver zur Herstellung einer Injektionslösung (bortezomib)

This is a summary of the risk management plan (RMP) for Bortezomib beta 3,5 mg Pulver zur Herstellung einer Injektionslösung. The RMP details important risks of Bortezomib beta 3,5 mg Pulver zur Herstellung einer Injektionslösung, how these risks can be minimised, and how more information will be obtained about Bortezomib beta 3,5 mg Pulver zur Herstellung einer Injektionslösung's risks and uncertainties (missing information).

Bortezomib beta 3,5 mg Pulver zur Herstellung einer Injektionslösung's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Bortezomib beta 3,5 mg Pulver zur Herstellung einer Injektionslösung should be used.

Important new concerns or changes to the current ones will be included in updates of Bortezomib beta 3,5 mg Pulver zur Herstellung einer Injektionslösung's RMP.

I. The medicine and what it is used for

Bortezomib beta 3,5 mg Pulver zur Herstellung einer Injektionslösung contains the active substance bortezomib, a so-called 'proteasome inhibitor'. Bortezomib can kill cancer cells by inhibiting the function of proteasomes, which play an important role in controlling cell function and growth.

Bortezomib beta 3,5 mg Pulver zur Herstellung einer Injektionslösung is authorised for the treatment of multiple myeloma and mantle cell lymphoma in patients older than 18 years (see SmPC for the full indication) It is administered either intravenously or subcutaneously.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Bortezomib beta 3,5 mg Pulver zur Herstellung einer Injektionslösung together with measures to minimise such risks and the proposed studies for learning more about Bortezomib beta 3,5 mg Pulver zur Herstellung einer Injektionslösung's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

II.A List of important risks and missing information

Important risks of Bortezomib beta 3,5 mg Pulver zur Herstellung einer Injektionslösung are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Bortezomib beta 3,5 mg Pulver zur Herstellung einer Injektionslösung. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

List of important risks and missing information	
Important identified risks	None
Important potential risks	None
Missing information	None

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Bortezomib beta 3,5 mg Pulver zur Herstellung einer Injektionslösung.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Bortezomib beta 3,5 mg Pulver zur Herstellung einer Injektionslösung.